Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shlipak

Showing results (1-10 of 736) with videos related to

Pageof 74
Sort By:
Clinical Evidence|September 16, 2006
Diabetic nephropathyMichael Shlipak
BMJ Clinical Evidence|May 19, 2009
Diabetic nephropathyMichael Shlipak
Clinical Evidence|April 20, 2006
Diabetic nephropathyMichael Shlipak
Clinical Evidence|May 4, 2005
Diabetic nephropathyMichael Shlipak
BMJ Clinical Evidence|March 23, 2011
Diabetic nephropathy: preventing progressionMichael Shlipak
Annals of Internal Medicine|June 5, 2003
Pharmacotherapy for heart failure in patients with renal insufficiencyMichael G Shlipak
Nature Clinical Practice. Nephrology|February 10, 2007
Cystatin C as a marker of glomerular filtration rate in chronic kidney disease: influence of body compositionMichael G Shlipak
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 26, 2008
Cystatin C: research priorities targeted to clinical decision makingMichael G Shlipak
Clinical Journal of the American Society of Nephrology : CJASN|May 17, 2015
Should Hemoglobin A1C Be Routinely Measured in Patients with CKD?Nisha Bansal, Michael G Shlipak
Current Opinion in Nephrology and Hypertension|September 2, 2020
Cystatin C is ready for clinical useNatalie Ebert, Michael G Shlipak
Pageof 74

Showing results (1-10 of 736) with videos related to

Sort By:
Pageof 74
Clinical Evidence|September 16, 2006
Diabetic nephropathyMichael Shlipak
BMJ Clinical Evidence|May 19, 2009
Diabetic nephropathyMichael Shlipak
Clinical Evidence|April 20, 2006
Diabetic nephropathyMichael Shlipak
Clinical Evidence|May 4, 2005
Diabetic nephropathyMichael Shlipak
BMJ Clinical Evidence|March 23, 2011
Diabetic nephropathy: preventing progressionMichael Shlipak
Annals of Internal Medicine|June 5, 2003
Pharmacotherapy for heart failure in patients with renal insufficiencyMichael G Shlipak
Nature Clinical Practice. Nephrology|February 10, 2007
Cystatin C as a marker of glomerular filtration rate in chronic kidney disease: influence of body compositionMichael G Shlipak
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 26, 2008
Cystatin C: research priorities targeted to clinical decision makingMichael G Shlipak
Clinical Journal of the American Society of Nephrology : CJASN|May 17, 2015
Should Hemoglobin A1C Be Routinely Measured in Patients with CKD?Nisha Bansal, Michael G Shlipak
Current Opinion in Nephrology and Hypertension|September 2, 2020
Cystatin C is ready for clinical useNatalie Ebert, Michael G Shlipak
Pageof 74